Viral load in the natural history of human papillomavirus type 16 infection: A nested case-control study

Journal of Infectious Diseases

Volumn 203, Issue 10, 2011, Pages 1425-1433

  Xi, Long Fu ^a,b   Hughes, James P ^c   Castle, Philip E ^e   Edelstein, Zoe R ^b   Wang, Chunhui ^b   Galloway, Denise A ^d   Koutsky, Laura A ^b   Kiviat, Nancy B ^a   Schiffman, Mark ^d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Department of Epidemiology ^*  (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CASE CONTROL STUDY; COLPOSCOPY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; MAJOR CLINICAL STUDY; MIXED INFECTION; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SMOKING; UTERINE CERVIX CARCINOMA IN SITU; VIRUS LOAD;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; LONGITUDINAL STUDIES; ODDS RATIO; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VIRAL LOAD; YOUNG ADULT;

EID: 79955001991     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir049     Document Type: Article

References (43)

1. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: Addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009; 4:8.
2. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) study group. J Natl Cancer Inst 1995; 87:796-802.
3. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, et al. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 2001; 358:1782-3. (Pubitemid 33153007)
4. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999; 180:1415-23. (Pubitemid 29506440)
5. Syrjanen S, Shabalova IP, Petrovichev N, et al. Clearance of high-risk human papillomavirus (HPV) DNA and Pap smear abnormalities in a cohort of women subjected to HPV screening in the New Independent States of the former Soviet Union (the NIS cohort study). Eur J Obstet Gynecol Reprod Biol 2005; 119:219-27. (Pubitemid 40460386)
6. Swan DC, Tucker RA, Tortolero-Luna G, et al. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J Clin Microbiol 1999; 37:1030-4. (Pubitemid 29140610)
7. Ylitalo N, Sorensen P, Josefsson AM, et al. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: A nested case-control study. Lancet 2000; 355:2194-8. (Pubitemid 30394326)
8. Josefsson AM, Magnusson PK, Ylitalo N, et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: A nested case-control study. Lancet 2000; 355: 2189-93. (Pubitemid 30394325)
9. Moberg M, Gustavsson I, Gyllensten U. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int J Cancer 2004; 112:854-9. (Pubitemid 39435271)
10. Fiander AN, Hart KW, Hibbitts SJ, et al. Variation in human papillomavirus type-16 viral load within different histological grades of cervical neoplasia. J Med Virol 2007; 79:1366-9. (Pubitemid 47106274)
11. Cricca M, Morselli-Labate AM, Venturoli S, et al. Viral DNA load, physical status and E2/E6 ratio as markers to grade HPV16 positive women for high-grade cervical lesions. Gynecol Oncol 2007; 106:549-57. (Pubitemid 47302471)
12. Moberg M, Gustavsson I, Wilander E, Gyllensten U. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer 2005; 92:891-4. (Pubitemid 40462636)
13. Lai HC, Peng MY, Nieh S, et al. Differential viral loads of human papillomavirus 16 and 58 infections in the spectrum of cervical carcinogenesis. Int J Gynecol Cancer 2006; 16:730-5.
14. Snijders PJ, Hogewoning CJ, Hesselink AT, et al. Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women with normal cytology. Int J Cancer 2006; 119:1102-7. (Pubitemid 44116920)
15. Lo KW, Yeung SW, Cheung TH, Siu NS, Kahn T, Wong YF. Quantitative analysis of human papillomavirus type 16 in cervical neoplasm: A study in Chinese population. J Clin Virol 2005; 34:76-80. (Pubitemid 41125880)
16. Lai CH, Chao A, Chang CJ, et al. Host and viral factors in relation to clearance of human papillomavirus infection: A cohort study in Taiwan. Int J Cancer 2008; 123:1685-92.
17. Fontaine J, Hankins C, Money D, et al. Human papillomavirus type 16 (HPV-16) viral load and persistence of HPV-16 infection in women infected or at risk for HIV. J Clin Virol 2008; 43:307-12.
18. Dalstein V, Riethmuller D, Pretet JL, et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: A longitudinal French cohort study. Int J Cancer 2003; 106: 396-403. (Pubitemid 36870403)
19. van Duin M, Snijders PJ, Schrijnemakers HF, et al. Human papillomavirus 16 load in normal and abnormal cervical scrapes: An indicator of CIN II/III and viral clearance. Int J Cancer 2002; 98:590-5. (Pubitemid 34208561)
20. Xi LF, Kiviat NB, Galloway DA, Zhou XH, Ho J, Koutsky LA. Effect of cervical cytologic status on the association between human papillomavirus type 16 DNA load and the risk of cervical intraepithelial neoplasia grade 3. J Infect Dis 2008; 198:324-31.
21. Xi LF, Hughes JP, Edelstein ZR, et al. Human papillomavirus (HPV) type 16 and type 18 DNA loads at baseline and persistence of typespecific infection during a 2-year follow-up. J Infect Dis 2009; 200:1789-97.
22. Rajeevan MS, Swan DC, Nisenbaum R, et al. Epidemiologic and viral factors associated with cervical neoplasia in HPV-16-positive women. Int J Cancer 2005; 115:114-20. (Pubitemid 40559675)
23. Cheung JL, Lo KW, Cheung TH, Tang JW, Chan PK. Viral load, E2 gene disruption status, and lineage of human papillomavirus type 16 infection in cervical neoplasia. J Infect Dis 2006; 194:1706-12. (Pubitemid 44902002)
24. Andersson S, Safari H, Mints M, Lewensohn-Fuchs I, Gyllensten U, Johansson B. Type distribution, viral load and integration status of high-risk human papillomaviruses in pre-stages of cervical cancer (CIN). Br J Cancer 2005; 92:2195-200. (Pubitemid 40966257)
25. Onan MA, Taskiran C, Bozdayi G, et al. Assessment of human papilloma viral load of archival cervical intraepithelial neoplasia by real-time polymerase chain reaction in a Turkish population. Eur J Gynaecol Oncol 2005; 26:632-5. (Pubitemid 43028058)
26. Molano M, Van den Brule A, Plummer M, et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: A population-based, 5-year follow-up study. Am J Epidemiol 2003; 158:486-94. (Pubitemid 37022847)
27. Kulmala SM, Shabalova IP, Petrovitchev N, et al. Type-specific persistence of high-risk human papillomavirus infections in the New Independent States of the former Soviet Union cohort study. Cancer Epidemiol Biomarkers Prev 2007; 16:17-22. (Pubitemid 46174258)
28. Constandinou-Williams C, Collins SI, Roberts S, Young LS, Woodman CB, Murray PG. Is human papillomavirus viral load a clinically useful predictive marker? A longitudinal study. Cancer Epidemiol Biomarkers Prev 2010; 19:832-7.
29. Monnier-Benoit S, Dalstein V, Riethmuller D, Lalaoui N, Mougin C, Pretet JL. Dynamics of HPV16 DNA load reflect the natural history of cervical HPV-associated lesions. J Clin Virol 2006; 35:270-7. (Pubitemid 43188972)
30. Crum CP, Beach KJ, Hedley ML, et al. Dynamics of human papillomavirus infection between biopsy and excision of cervical intraepithelial neoplasia: Results from the ZYC101a protocol. J Infect Dis 2004; 189:1348-54. (Pubitemid 38543582)
31. Ho CM, Cheng WF, Chu TY, et al. Human papillomaviral load changes in low-grade squamous intraepithelial lesions of the uterine cervix. Br J Cancer 2006; 95:1384-9.
32. Schiffman M, Adrianza ME. ASCUS-LSIL Triage Study. Design, methods and characteristics of trial participants. Acta Cytol 2000; 44:726-42.
33. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003; 188: 1383-92.
34. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000; 38: 357-61. (Pubitemid 30043317)
35. Blizzard L, Hosmer DW. The log multinomial regression model for nominal outcomes with more than two attributes. Biom J 2007; 49:889-902.
36. Slinker BK, Glantz SA. Multiple linear regression is a useful alternative to traditional analyses of variance. Am J Physiol 1988; 255: R353-67.
37. Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995; 87:1365-71.
38. Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001; 286:3106-14. (Pubitemid 34016525)
39. Ylitalo N, Josefsson A, Melbye M, et al. A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ. Cancer Res 2000; 60: 6027-32.
40. Remmink AJ, Walboomers JM, Helmerhorst TJ, et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: Natural history up to 36 months. Int J Cancer 1995; 61:306-11.
41. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: A prospective study. Lancet 1999; 354:20-5. (Pubitemid 29304297)
42. Rodriguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008; 100:513-7.
43. Rodriguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: Critical role of duration of infection. J Natl Cancer Inst 2010; 102:315-24.